Research that is free to access for all investors. Companies commission these providers to write research about them.
Brokers who write research on their corporate clients and make it available through our main bundle offering.
Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.
Event in Progress:
Research Tree provides access to ongoing research coverage, media content and regulatory news on Dignitana AB. We currently have 0 research reports from 0 professional analysts.
Companies: Warpaint London PLC
Shore Capital
Diaceutics has reported results for 1H24 in accordance with the trading statement from July which translated into a net loss for the half of £2.6m with negative EBITDA of £1.3m. The reduced financials reflect the continuing high pace of development and data acquisition for the DXRX platform together with an increased focus on marketing, which raised costs; head count ended the period at 206, 28% higher YoY. However, the company reiterated its guidance that the two-year phase of accelerated inves
Companies: Diaceutics Plc
Capital Access Group
Companies: BILN CRU AGY JNEO
Cavendish
The UK industrial sector continues to show promising signs of recovery, with manufacturing PMI reaching a 26-month high of 52.5 in August as all survey indicators but one expanded. Economic data has also been encouraging, with UK pay growth cooling to a two-year low and inflation rising only slightly in July – supporting the case for further interest rate cuts this year by the BoE.
Companies: TAND AVON BMTO CGS GHH PEN SCE RCDO SOLI TRI SYM IGE JDG PEG CSSG ABDP PODP KETL LIFS SPSY
Zeus Capital
Interims results show a strong improvement in margins and cash generation as a result of self-help measures and strong execution from management taking effect. The outlook remains positive, with H2 looking well underpinned by orders already received in the Point-of-Care division and further growth from the newly commissioned Life Sciences manufacturing plant in South Bend. We make no changes to our forecasts at this stage and flag the mid-teens EBITDA growth outlook and attractive earnings multi
Companies: EKF Diagnostics Holdings plc
Singer Capital Markets
Canaccord Genuity
Allergy Therapeutics has announced that the second cohort of allergic patients in its phase 1/2a clinical trial of VLP Peanut, PROTECT, has now completed dosing. Patients in this cohort received up to a 50-fold dose increase from the initial dose following three further incremental increases in dose and, importantly, no relevant safety or tolerability issues were observed at these higher doses. This announcement follows the June 2024 update that reported the first cohort of patients had complete
Companies: Allergy Therapeutics plc
Companies: Scancell Holdings Plc
Panmure Liberum
Companies: Next plc (NXT:LON)Warpaint London PLC (W7L:LON)
16th September 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: Vector Capital (VCAP.L) has delisted from AIM What’s baking in the oven? Our daily digest of news from UK Small Caps If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”. Hybridan Chefs resea
Companies: MTEC SNX SAR SIS KMK ADF
Hybridan
17th September 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour *New product launch* In addition to our Small Cap Feast, which will continue to bring you the latest IPO news and stories across the small cap universe, we will shortly be launching “Friday Takeaway”. This will delve a little deeper on individual companies and focus on non-h
Companies: CRU MDZ DPP PYC DXRX ZIN BMN HE1
Detailed data from the Phase I study in Type II diabetes (T2D) of Arecor’s lead asset AT278, a unique ultra-rapid and ultra-concentrated insulin, were presented at the European Association for the Study of Diabetes (EASD) 2024 meeting. These data confirm its attractive profile, with faster onset and stronger early glucose-lowering effect in comparison to gold standard fast-acting insulin NovoRapid/NovoLog (NovoNordisk). Clinical data to date suggest a pertinent and highly differentiated profile
Companies: Arecor Therapeutics PLC
Trinity Delta
We have upgraded our revenue forecasts and valuation following interim results and the earlier and imminent US launch by partner Haleon, which we previously anticipated in 2025. The US launch, expected in October, will trigger a milestone and recurring royalties on net Eroxon sales. Commercial success in the US will be transformational, ensuring Futura’s sustainable and growing profitability. Meanwhile, existing partners outside of the US continue to execute on launches, with Eroxon now availabl
Companies: Futura Medical plc
Shield is a commercial-stage pharma company delivering specialty products that address the unmet medical need of patients with iron deficiency (ID). Since its July 2021 US launch, Shield and Viatris have increased physician awareness of the differentiating characteristics of ACCRUFeR® as an oral ID drug, in order to generate sales traction. 1H’24 results have confirmed that sales continue to progress well, while costs have been closely controlled. Management is focused on successful execution an
Companies: Shield Therapeutics Plc
Hardman & Co
Companies: FOG ELCO RNO TIA TRX HVO NXQ ANIC BOOM LORD
